Kaltner Herbert, Szabó Tamás, Fehér Krisztina, André Sabine, Balla Sára, Manning Joachim C, Szilágyi László, Gabius Hans-Joachim
Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig-Maximilians-University Munich, Veterinärstr. 13, 80539 München, Germany.
Department of Chemistry, University of Debrecen, PO Box 20, 4010 Debrecen, Hungary; Richter Gedeon Rt., Gyömröi út 19-21, 1103 Budapest, Hungary.
Bioorg Med Chem. 2017 Jun 15;25(12):3158-3170. doi: 10.1016/j.bmc.2017.04.011. Epub 2017 Apr 9.
The emerging significance of recognition of cellular glycans by lectins for diverse aspects of pathophysiology is a strong incentive for considering development of bioactive and non-hydrolyzable glycoside derivatives, for example by introducing S/Se atoms and the disulfide group instead of oxygen into the glycosidic linkage. We report the synthesis of 12 bivalent thio-, disulfido- and selenoglycosides attached to benzene/naphthalene cores. They present galactose, for blocking a plant toxin, or lactose, the canonical ligand of adhesion/growth-regulatory galectins. Modeling reveals unrestrained flexibility and inter-headgroup distances too small to bridge two sites in the same lectin. Inhibitory activity was first detected by solid-phase assays using a surface-presented glycoprotein, with relative activity enhancements per sugar unit relative to free cognate sugar up to nearly 10fold. Inhibitory activity was also seen on lectin binding to surfaces of human carcinoma cells. In order to proceed to characterize this capacity in the tissue context monitoring of lectin binding in the presence of inhibitors was extended to sections of three types of murine organs as models. This procedure proved to be well-suited to determine relative activity levels of the glycocompounds to block binding of the toxin and different human galectins to natural glycoconjugates at different sites in sections. The results on most effective inhibition by two naphthalene-based disulfides and a selenide raise the perspective for broad applicability of the histochemical assay in testing glycoclusters that target biomedically relevant lectins.
凝集素识别细胞聚糖在病理生理学各个方面的新意义,有力地推动了人们考虑开发具有生物活性且不可水解的糖苷衍生物,例如通过在糖苷键中引入硫/硒原子和二硫键来替代氧原子。我们报道了12种连接在苯/萘核心上的二价硫代、二硫代和硒代糖苷的合成。它们呈现半乳糖以阻断植物毒素,或乳糖,即黏附/生长调节半乳糖凝集素的典型配体。模型显示其具有不受限制的灵活性,且头基间距离过小,无法桥接同一凝集素中的两个位点。首先通过使用表面呈现的糖蛋白的固相测定法检测到抑制活性,相对于游离的同源糖,每个糖单元的相对活性增强高达近10倍。在凝集素与人癌细胞表面结合时也观察到了抑制活性。为了进一步在组织环境中表征这种能力,将在抑制剂存在下对凝集素结合情况的监测扩展到三种类型的小鼠器官切片作为模型。该方法被证明非常适合确定糖化合物在切片不同位点阻断毒素和不同人类半乳糖凝集素与天然糖缀合物结合的相对活性水平。基于萘的两种二硫化物和一种硒化物的最有效抑制结果,为组织化学测定法在测试靶向生物医学相关凝集素的糖簇方面的广泛应用带来了前景。